Important limitations
- Individual claims and source links have not yet completed editorial verification.
- Evidence level, applicable study model, formulation, route and population remain unassigned.
Vilon
Vilon is the dipeptide Lys-Glu, developed in the 1990s by Vladimir Khavinson and Vyacheslav Morozov in St.
Dosing & scaling, explained
The moderated mass amounts below are retained for comparison. Near-duplicates, mix-dependent volumes and device markings are excluded. This is educational source context, not a protocol or recommendation.
Mass amounts available for comparison
- Lower range1 mgDose
Recorded example with no verified study backing; shown for amount literacy only.
- Mid range5 mgDose
Recorded example with no verified study backing; shown for amount literacy only.
Only mcg or mg amounts are retained. The calculator derives mL, syringe units or pen clicks from the current vial strength, water volume and device.
No independently verified schedule
Evidence context
No clinical amount or schedule is inferred from this material. Source verification is pending, and every displayed amount remains educational context rather than guidance.
Storage, handling and interpretation
Product identity
Verify the exact compound, formulation and amount against the product label or certificate before calculation.
Storage & handling
Follow the product label, certificate and validated laboratory SOP; no universal storage assumption is applied here.
Prepared solutions
Label concentration and preparation date, use sterile technique where applicable, and follow a validated stability protocol.
Reported protocols for Vilon
What published studies and recent community write-ups report about amounts, timing and course length. 3 clinical, 3 preclinical and 2 community-reported rows, each linked to its source. These are descriptions of what others report, not instructions, and nothing here is medical advice.
| Context | Dose | Frequency | Route | Course | Source |
|---|---|---|---|---|---|
| Clinical3 rows | |||||
| Double-blind randomized study in surgical patients63 surgical patients: 33 aged 18-77 with acute purulent inflammation of the face and jaw and 30 aged 24-45 with cervical dysplasia or carcinoma in situ | 10 mcg | Once daily for 7 or 10 days | Intramuscular | 7-10 daysNot applicable | Advances in Gerontology (Springer)2014 |
| The developers' 2014 review reports that adding Vilon to standard care sped tissue repair and recovery, shifted several blood and immune indices and shortened rehabilitation without side effects. The underlying study is Russian-language and the review gives no effect sizes, so the claim cannot be checked independently. | |||||
| Adjuvant courses after colorectal cancer surgery57 patients with colorectal cancer, 80.6% over 50 and 47.3% over 60, after radical surgery or during spread of the disease | 1 mg | Once daily for 10 days | Injection (route not specified in the review) | Three 10-day courses at 1-month intervalsAbout 3 weeks between courses | Advances in Gerontology (Springer)2014 |
| The review states that everyone who completed three courses was recurrence-free at one year and that two-year survival was 85.8% against 37% in controls, with fewer chemotherapy complications. The original 2005 report calls its own results preliminary and its English abstract does not describe how the control group was formed, so the survival difference should be read with caution. | |||||
| Chronic periodontitis in older adults with diabetes or vascular diseaseMore than 250 people aged 65-87 with chronic periodontitis alongside type 2 diabetes, atherosclerosis or other cardiovascular disease | 10-20 mcg | Once daily for 5-10 days | Submucosal injection into the gums | 5-10 daysNot applicable | Advances in Gerontology (Springer)2014 |
| Immune indices, phagocytic activity, complement, lipid peroxidation and antioxidant measures in blood and saliva were reported to improve and markers of intravascular coagulation to fall. The same review notes that the changes were smaller than in younger patients with periodontitis, and no control group is described. | |||||
| Preclinical3 rows | |||||
| HER-2/neu transgenic mice (mammary cancer model)Female FVB/N HER-2/neu transgenic mice from 2 months of age | 1 mcg per mouse | 5 consecutive days every month | Subcutaneous | Lifelong monthly pulsesAbout 25 days off each month | International Journal of Cancer (PubMed)2002 |
| In this model Vilon had a negative effect: mammary cancer incidence rose, tumours appeared earlier and the cumulative number of tumours increased compared with saline, while the tetrapeptide Epitalon given the same way reduced tumour number and size. It is the clearest published safety signal for the peptide. | |||||
| Chemically induced bowel tumours in miceMice given 1,2-dimethylhydrazine to induce intestinal neoplasia | 10 mcg/kg | Repeated dosing (schedule not given in the English abstract) | Not stated in the abstract | Followed to 46 weeksNot applicable | Voprosy Onkologii (PubMed)2005 |
| Tumours developed in 14.3% of treated mice that survived to the first tumour detection versus 60% of controls, and preneoplastic kidney changes were also reduced. The paper is in Russian and only the abstract is available in English. | |||||
| Sexual function in old male ratsOld hemigonadectomised male rats used as a model of age-related decline | 50 mcg per rat | Regular administration (interval not given in the abstract) | Not stated in the abstract | Not statedNot applicable | Advances in Gerontology (PubMed)2006 |
| Treated rats showed more sexual activity and changes in LH, prolactin, ACTH and hypothalamic neurotransmitters, with a fall in prolactin highlighted by the authors. The abstract gives no group sizes or statistics. | |||||
| Community-reported2 rows | |||||
| Community immune and longevity course | 5-10 mg (most often 10 mg) | Once daily | Subcutaneous or intramuscular | 5-12 consecutive days (10 days in the anti-aging variant)Repeated every 3-6 months, or twice a year | Community resource2025 |
| This December 2025 blog post lays out 10 mg a day for 5 to 10 days every 3 to 6 months for immune and longevity goals and the same dose for 10 straight days twice a year for regeneration, and states that the mouse lifespan study used 0.1 mcg per animal. The author sells through an affiliated vendor and does not explain how the milligram doses were derived from microgram animal and clinical data. | |||||
| Capsule or vial course in the Khavinson pattern | 1-2 Cytomed capsules per day, or 1-2 mg subcutaneously (5 mg vial in 2.5 mL gives 2 mg/mL) | Once daily | Oral capsules before breakfast, or subcutaneous injection | 10-30 day courses (about 10 days for the vial pattern)Repeated once or twice a year, often paired with Thymogen | Community resource2026 |
| A calculator site's August 2026 page describes the Russian capsule and the research vial as separate products and warns that powder sold abroad as Thymalin is sometimes mislabelled Lys-Glu. It rates the evidence as low and treats the 10-day course repeated twice a year as the school's convention rather than a tested schedule. | |||||
How a course is commonly described
- Days 1-10: courseCommunity-reported
Community guides describe a short daily pulse, 1-2 mg or up to 10 mg subcutaneously, for 5 to 10 days, or one to two capsules a day for 10 to 30 days. One site places the start of any immune or neuroendocrine effect within this first course without citing a measurement.
- Months 3-6: repeat courseCommunity-reported
Courses are repeated every 3 to 6 months or twice a year, with the months in between left untreated. Community pages attribute lower inflammatory markers and better regulatory T-cell function to repeated courses, again without trial data.
- Clinical comparison: microgram coursesClinical
The Russian clinical reports used 10 mcg intramuscularly once a day for 7 to 10 days, 10 to 20 mcg into the gums for 5 to 10 days, or 1 mg a day for 10 days repeated three times a month apart in cancer patients. Even the largest of these is a tenth of the common community dose, and the diabetes report, which described normalized immune and clotting measures and a lower insulin requirement, does not give a dose in its abstract.
- Preclinical comparison: lifelong monthly pulsesPreclinical
The lifespan study gave female CBA mice subcutaneous Vilon from the sixth month of life onward and reported more activity, lower body temperature, longer life and fewer spontaneous tumours, with no harm to development; the transgenic study used 1 mcg per mouse for 5 days each month. These are lifelong intermittent regimens, not the few courses a year described online.
- Community milligram doses are 100 to 1,000 times the 10 to 20 mcg courses in the Russian clinical literature; only the colorectal cancer report used as much as 1 mg a day. No human pharmacokinetic study of Vilon has been published.
- Tumour findings are mixed: fewer spontaneous and chemically induced tumours in several rodent studies, but more mammary tumours and shorter latency in HER-2/neu transgenic mice. Guides that mention this advise against use with a cancer history.
- Vilon is not approved outside Russia. Research vials are unregulated, and the capsule sold as a supplement is a different product from the injected courses in the trials.
Sources for this section (10)
- Peptide bioregulators: A new class of geroprotectors, report 2. The results of clinical trials
- Application of peptide bioregulator in complex treatment of elderly cancer patients
- Effect of vilon on the immunity status and coagulation hemostasis in patients of different age with diabetes mellitus
- Inhibitory effect of the peptide epitalon on the development of spontaneous mammary tumors in HER-2/neu transgenic mice
- The effect of vilon (Lys-Glu) on 1,2-dimethylhydrazine-induced neoplasia
- Effect of vilon on neuroendocrine status and sexual function of old male rats
- Effect of vilon on biological age and lifespan in mice
Plus 3 community resources (dosing guides, forum threads and vendor write-ups), reported above but not linked.
Overview
Vilon is the dipeptide Lys-Glu, developed in the 1990s by Vladimir Khavinson and Vyacheslav Morozov in St. Petersburg as the shortest synthetic descendant of the thymus extract Thymalin, and promoted as an immune and geroprotective bioregulator that acts on chromatin and gene expression. Russian studies in mice and rats reported longer lifespan and fewer spontaneous or chemically induced tumours, but one transgenic breast cancer model showed more mammary tumours, and the clinical literature from the same group describes microgram-scale courses (10 to 20 mcg a day for 5 to 10 days) in surgical, periodontal and diabetic patients plus a 1 mg daily course in colorectal cancer patients. It has no approval outside Russia, where the same dipeptide is also sold as Normophthal for eye use; abroad it is sold as research vials or as Cytomed capsules, and community guides describe 1 to 10 mg injections for 5 to 30 days a few times a year, which is 100 to 1,000 times the doses in the Russian trials.
What researchers are exploring
These themes organize the educational information currently available. Individual claims remain under source review and are not treatment claims.
- 1
Research on Vilon
Vilon’s Role in Chromatin Structure Regulation Vilon is known for its potent ability to regulate chromatin structure. Research indicates that it induces the unrolling of chromatin, activates synthetic processes by…
What is known and what still needs verification
Available context is organized without assigning unsupported study models or evidence grades.
- Not graded
Research on Vilon
Vilon’s Role in Chromatin Structure Regulation Vilon is known for its potent ability to regulate chromatin structure. Research indicates that it induces the unrolling of chromatin, activates synthetic processes by reactivating ribosomal genes within unrolled…
Amounts recorded for Vilon
These amount records are independent from vial strength, reconstitution volume and measuring device. A recorded source is not the same as study backing, and these values are not recommendations.
- 1Dose · lower endpointSign in for schedule, duration and source context.1 mg
- 2Dose · upper endpointSign in for schedule, duration and source context.5 mg
Chemistry identifiers
Sequence, synonyms and registry identifiers as recorded in PubChem, the National Library of Medicine's open chemistry database. Formula, mass and CAS number are summarized at the top of the page.
Sequence
Lys-Glu
Also listed as
Lys-Glu, KE dipeptide, Peptide vilon, Normophthal, L-Lysyl-L-glutamic acid, UNII H34V7IM5ML, CHEBI:74557, CHEMBL365790
InChIKey
UGTZHPSKYRIGRJ-YUMQZZPRSA-N
IUPAC name
(2S)-2-[[(2S)-2,6-diaminohexanoyl]amino]pentanedioic acid
Limitations and unknowns
Sources
1 link carried over from the earlier page, awaiting verification.